A key question in tuberculosis control is why some strains of M. tuberculosis are preferentially associated with resistance to multiple drugs. We demonstrate that M. tuberculosis strains from lineage 2 (East Asian lineage and Beijing sublineage) acquire drug resistances in vitro more rapidly than M. tuberculosis strains from lineage 4 (Euro-American lineage) and that this higher rate can be attributed to a higher mutation rate. Moreover, the in vitro mutation rate correlates well with the bacterial mutation rate in humans as determined by whole-genome sequencing of clinical isolates. Finally, using a stochastic mathematical model, we demonstrate that the observed differences in mutation rate predict a substantially higher probability that patients infected with a drug-susceptible lineage 2 strain will harbor multidrug-resistant bacteria at the time of diagnosis. These data suggest that interventions to prevent the emergence of drug-resistant tuberculosis should target bacterial as well as treatment-related risk factors.
A r t i c l e s Recently, strains of M. tuberculosis have emerged that are resistant to most or all effective antibiotics [1] [2] [3] [4] . Given the low mutation rate of M. tuberculosis 5, 6 and its slow replication rate, it is unclear how the bacterium acquires resistance to multiple antibiotics, especially in the face of concurrent multiple-drug treatment. The most commonly cited risk factors for treatment failure due to antibiotic resistance are patient noncompliance [1] [2] [3] [4] [7] [8] [9] , inappropriate drug regimens and dosing 2, 5, 6, 9, 10 , and primary infection with drug-resistant strains 11, 12 . The relative contributions of bacterial determinants to treatment failure have been unclear. Recently, whole-genome sequencing of M. tuberculosis isolates showed the key role of newly arising mutation in the emergence of drug resistance [13] [14] [15] . Sequencing of M. tuberculosis from patients in whom antibiotic therapy was unsuccessful showed that new mutations conferring antibiotic resistance can arise multiple times within a given individual 15 . Moreover, several studies suggest that certain strains of M. tuberculosis may be more frequently associated with multidrug resistance (MDR) 16, 17 . Given that all drug resistance in M. tuberculosis occurs through chromosomal mutation, these data suggest that the mutational capacity of the bacterium may be a key determinant of the likelihood of developing drug resistance.
M. tuberculosis forms phylogeographic lineages associated with particular human populations [18] [19] [20] [21] . Although M. tuberculosis is less genetically diverse than many other pathogens, there is both experimental and clinical evidence that M. tuberculosis strains from different lineages vary in their capacity to cause disease [20] [21] [22] [23] [24] and acquire drug resistance 11, 12, 16, 20, [25] [26] [27] [28] . Specifically, M. tuberculosis strains in lineage 2 (the East Asian lineage, which includes the Beijing family of strains) have been epidemiologically associated with increased risk of drug resistance in several cross-sectional studies in diverse locales, although not in all 29 . Strains from this lineage have polymorphisms in genes involved in DNA replication, recombination and repair relative to strains from lineage 4 (the Euro-American lineage), raising the possibility that they are more mutable than other M. tuberculosis strains 30 . However, these epidemiological observations might also reflect social and programmatic factors (such as noncompliance and inappropriate dosing) correlating with the phylogeography of the lineage 2 strains. Indeed, in vitro studies comparing the rate of acquisition or the frequency of drug resistance in lineage 2 and lineage 4 strains have produced differing results 31, 32 . Here we sought to determine the rate at which M. tuberculosis strains of different lineages acquire drug resistance and the effect of strain-based differences in mutation rate on the predicted de novo generation of MDR in individuals with tuberculosis.
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis A r t i c l e s
RESULTS

Effect of mutation and genetic background on drug resistance
To measure the rate at which drug resistance is acquired in strains from different M. tuberculosis lineages, we performed Luria-Delbrück fluctuation analysis 33, 34 on a panel of laboratory and clinical isolates from both lineage 2 and lineage 4. All strains were fully drug susceptible, with minimum inhibitory concentrations (MICs) at least 100-fold lower than the drug concentrations at which we assessed the acquisition of drug resistance (MIC (rifampicin) < 0.015 µg/ml; MIC (isoniazid) < 0.007 µg/ml; Supplementary Table 1 ). Within both lineages, there was some strain-to-strain variation in the rate at which rifampicin resistance was acquired ( Fig. 1) . However, every strain from lineage 2 acquired resistance to rifampicin (2 µg/ml) at a significantly higher rate than every lineage 4 strain, with a nearly tenfold difference between the means of the two groups ( Fig. 1 and Supplementary Table 1 ).
The higher rate of acquisition of rifampicin resistance in lineage 2 strains could reflect three possible mechanisms: (i) differences in ability to survive and mutate after exposure to antibiotic, (ii) inherent differences in the number of rpoB mutations conferring rifampicin resistance (target size) or (iii) differences in the basal mutation rate in the absence of selection. To test these hypotheses, we chose wellcharacterized representatives from lineage 2 and lineage 4-HN878 and CDC-1551, respectively-for further study.
Differences in response to antibiotic
We first sought to determine whether lineage 2 and lineage 4 strains differed in their ability to acquire drug resistance after exposure to rifampicin. Fluctuation analysis assumes that all mutations occur before selection and that all mutants replicate as well as wild type 33 ; however, if a strain is capable of surviving and mutating in the presence of a drug, it will produce a greater number of drug-resistant mutants. Building on similar studies in Saccharomyces cerevisiae 35 , we reasoned that, if mutations occur in the presence of a drug, then lowering the drug concentration might allow strains from both lineages to grow and acquire mutations following exposure. Conversely, increasing the drug concentration might abrogate the ability of both strains to survive and acquire mutations in the presence of the drug. However, we found that statistically significant increases in the acquisition rate of rifampicin resistance for the lineage 2 strain HN878 relative to the lineage 4 strain CDC-1551 were maintained over tenfold variation in drug concentration (0.5-5 µg/ml) ( Fig. 2 and Supplementary Table 1 ).
To extend these findings, the distribution of mutants observed in each fluctuation assay can be analyzed using previously developed tools 35 . This analysis takes advantage of the fact that mutations occurring in culture, before antibiotic exposure, result in a Luria-Delbrück distribution of mutants (number of mutants per culture). Although mutations arise according to a Poisson distribution, the subsequent outgrowth of mutants in broth culture generates a Luria-Delbrück distribution. In contrast, mutations occurring after plating with antibiotic occur according to a Poisson distribution, without the expansion in broth culture that creates a Luria-Delbrück distribution 33, 36, 37 . Thus, the appearance of any additional mutants resulting from the acquisition of resistance after antibiotic exposure will generate a mixed distribution of mutants, containing mutants with a Poisson distribution arising after plating with drug and mutants with a Luria-Delbrück distribution arising before drug exposure.
We therefore used a curve-fitting approach to determine whether the distribution of mutants (number of mutants per culture) in the two lineages was better fit using a one-parameter Luria-Delbrück model or a two-parameter Luria-Delbrück and Poisson mixture model ( Fig. 3a-f ). The algorithm first fits the data to a Luria-Delbrück model alone and then optimizes the fit with the addition of a Poisson model. A purely Poisson model was also fit to serve as a reference. We used the Akaike information criterion with correction for sample size (AIC C ) to identify instances where the Luria-Delbrück model alone provided optimal fit compared to either the Poisson model or the two-parameter mixture model 38, 39 . AIC C quantifies the evidence in favor of choosing a more complex model (here, the two-parameter mixture model) over a simpler model Table 2 ). More revealing, ∆AICc (AIC C (Luria-Delbrück model) -AIC C (two-parameter model)) was also negative, indicating that there was insufficient evidence to support the inclusion of an additional Poisson component in the Luria-Delbrück distributions ( Fig. 3g and Supplementary  Table 2 ). This finding suggests that mutation acquired after exposure to antibiotic is not responsible for the higher rate with which the lineage 2 strain HN878 acquires rifampicin resistance. This analytic approach also suggests that the difference in the rates at which rifampicin resistance occurs is not due to strain-based differences in the fitness effects of the mutations conferring drug resistance 33, 37 . If the drug-resistant mutants in either strain were subject to a high fitness cost, the outgrowth of mutants in culture before selection would have been slower than that of drug-susceptible cells, driving the Luria-Delbrück distribution back toward the underlying Poisson distribution of mutation. However, our data suggest that, in both strains, drug-resistant mutants occur primarily according to a Luria-Delbrück distribution.
Differences in target size
Rifampicin resistance is encoded by multiple mutations in the rifampicin resistance-determining region (RRDR) of rpoB. Strains in which there are a greater number of potential mutations in the RRDR that produce drug resistance would more rapidly acquire resistance to rifampicin. Therefore, we sought to determine whether M. tuberculosis strains of different lineages differ in the total number of mutations that confer rifampicin resistance, accounting for differences in the rates at which rifampicin resistance occurs. We sequenced the RRDR of rpoB in 600 independent mutants (100 from each fluctuation assay in Fig. 2 ) to determine the number of mutations conferring rifampicin resistance in both strains under each condition tested ( Fig. 4a and Supplementary Table 3 ). Although there is potentially a discrepancy between the mutations conferring drug resistance that f Figure 3 The cumulative distribution of drug-resistant mutants from lineage 2 and lineage 4 indicates that mutations do not occur after exposure to antibiotic. (a-f) Curve-fitting analysis was performed to determine whether the cumulative distribution of the fluctuation analysis data for strains plated in antibiotic better fit a one-parameter Luria-Delbrück model, a one-parameter Poisson model or a two-parameter Luria-Delbrück and Poisson mixture model. The number of mutants per culture is shown on the x axis, and the probability of observing x or fewer mutants per culture is shown on the y axis. Results are shown for lineage 4 strain CDC-1551 plated on rifampicin (0.5 µg/ml) (a), lineage 2 strain HN878 plated on rifampicin (0.5 µg/ml) (b), lineage 4 strain CDC-1551 plated on rifampicin (2 µg/ml) (c), lineage 2 strain HN878 plated on rifampicin (2 µg/ml) (d), lineage 4 strain CDC-1551 plated on rifampicin (5 µg/ml) (e) and lineage 2 strain HN878 plated on rifampicin (5 µg/ml) (f). (g) To determine which model best fit each data set, we determined AIC C values.
A smaller AIC C represents a better fit given a penalty for more parameters in a model. If AIC C (Luria-Delbrück model) is smaller than AIC C (twoparameter model), then the resulting value will be negative, reflecting a better fit for the Luria-Delbrück model (supplementary table 2 ). 40 , all of the mutations that we identified corresponded to mutations seen clinically 41 . For both strains, the target size became smaller as drug concentration increased, indicating that some rpoB mutations generate lower level rifampicin resistance. There were small differences in target size between the two strains at two of the three drug concentrations tested, such that the numbers of mutations conferring resistance at both 0.5 and 2 µg/ml were higher in the lineage 2 strain. These data suggest that target size differences between strains contribute to strain-based differences in the acquisition of rifampicin resistance. However, correcting for target size to determine the per-base mutation rate, we found that the lineage 2 strain HN878 still had a significantly higher rate at which resistance was required compared to the lineage 4 strain CDC-1551 at each of the drug concentrations tested ( Fig. 4b and Supplementary Table 4 ). Therefore, it is likely that differences in basal mutation rate lead to differences in the acquisition of rifampicin resistance.
Resistance to other antibiotics
If the mutation rate of HN878 is higher than that of CDC-1551, then the lineage 2 M. tuberculosis strain should also acquire resistances to other antibiotics at a higher rate. We therefore assessed the rates at which HN878 and CDC-1551 acquired resistance to ethambutol (5 µg/ml) and isoniazid (1 µg/ml). For both antibiotics, the rate of resistance was nearly 3-fold (2.51-fold and 2.75-fold, respectively) higher in the lineage 2 strain HN878, consistent with the increased rate at which this strain acquired rifampicin resistance ( Fig. 5 and Supplementary Table 1 ). Taken together, these results suggest that M. tuberculosis strains from lineage 2 have a higher basal mutation rate than strains from lineage 4.
In vitro mutation rates to predict in vivo resistance
We then sought to understand how these in vitro measures of mutation translate to the in vivo environment. In our previous work, we determined that, in nonhuman primates, M. tuberculosis mutates at a relatively fixed rate over time, and this in vivo per-day mutation rate is well approximated by the in vitro per-day mutation rate as measured by fluctuation analysis and adjusted for target size 6 . To determine whether the in vitro mutation rate is similarly concordant with the mutation rate of M. tuberculosis during human infection, we analyzed the whole-genome sequences of M. tuberculosis isolates derived from an outbreak of a lineage 4 strain in British Columbia, Canada 42 . We determined the number of SNPs in each strain relative to a historical isolate, identifying SNPs according to parameters that were experimentally validated through Sanger resequencing in our previous work ( Fig. 6a) . By reconstructing the phylogeny of these strains through Bayesian Markov chain Monte Carlo (MCMC) analysis 43, 44 (Supplementary Fig. 1 ) and informing the phylogeny with dates for each isolate, we have estimated the base substitution rate (equivalent to the mutation rate under a neutral model of evolution 45 ) in this outbreak. Notably, we found that the British Columbia strains acquired mutations at approximately the same rate over time as previously shown for M. tuberculosis strains isolated from macaques with active and latent disease, irrespective of disease course ( Fig. 6b and Supplementary Table 5 ). In addition, the rate at which these strains acquired mutations in vivo was well approximated by the in vitro per-day mutation rate of the lineage 4 strain (Erdman) used in the macaque infections as defined by fluctuation analysis. Finally, consistent with both our previous work 6 and the work of others 46 , these data indicate that a molecular clock of 0.3-0.5 mutations per genome per year may be applicable to the analysis of M. tuberculosis genetic diversity over the time scales assessed here (approximately 10 years).
A model of drug resistance predicts MDR before treatment
Given these data, we developed a stochastic simulation model of the evolution of drug resistance within an infected human host to assess the potential clinical impact of the observed differences in mutation rate between lineage 2 and lineage 4 strains. Our model of drug resistance uses a stochastic mutation parameter in which mutation occurs at a constant rate over time, and we informed this parameter with the in vitro mutation rates for CDC-1551 and HN878 as proxies Figure 5 A representative lineage 2 strain acquires isoniazid and ethambutol resistance at a higher rate than a strain from lineage 4. Fluctuation analysis was used to determine the rates at which the lineage 4 strain CDC-1551 and the lineage 2 strain HN878 acquired resistance to isoniazid (1 µg/ml) and ethambutol (5 µg/ml Figure 6 Bayesian MCMC analysis shows a mutation rate in humans similar to that estimated in strains from the macaque model and in vitro.
(a) The number of SNPs and the number of days separating clinical isolates and MT0005 are plotted. SNPs located in repeat regions (PE_PGRSs, PPEs and transposable elements) were excluded, consistent with our previous analysis 6 . The data are fit to a first-order polynomial to show the trend (dark blue line). (b) Estimates of mutation rate in human isolates were derived by reconstructing the phylogeny of the isolates in a. Mutation rate is shown on the y axis in log scale. Estimates of mutation rate from the macaque model and the infecting strain Erdman (in vitro) were determined previously 6 . Error bars represent 95% confidence intervals.
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A r t i c l e s for their mutation rates in the human host ( Supplementary Fig. 2a and Supplementary Table 6 ). We used this model to simulate the emergence of MDR (defined here as resistance to both rifampicin and isoniazid) in an infected individual before diagnosis and treatment (Supplementary Fig. 2b ).
In the model, as a result of the differences in mutation rate, individuals infected with the lineage 2 strain HN878 were at a notably increased risk of acquiring MDR before treatment compared to individuals infected with the lineage 4 strain CDC-1551 ( Fig. 7a) . When all other parameters (bacterial birth and death rates, fitness and bacterial burden at the time of diagnosis) were kept equal, the difference in the probability of MDR before diagnosis and treatment was approximately 22-fold. We found similar results when using an alternative model of drug resistance in which mutation is replication rather than time dependent (Supplementary Fig. 2c) 47 . We assessed the sensitivity of our model to fluctuations in both growth rate and fitness (Fig. 7b,c) . Varying these parameters did not alter our principal conclusion that individuals infected with lineage 2 strains of M. tuberculosis are at notably higher risk of the de novo acquisition of MDR, reflecting the multiplicative effects of the increased risks associated with acquiring resistance to individual drugs due to a higher basal mutation rate.
DISCUSSION
Here we demonstrate that strains from lineage 2 of M. tuberculosis (the East Asian lineage, which includes the Beijing family of strains) acquire resistance to drugs in vitro more rapidly than strains from lineage 4 (the Euro-American lineage). This difference is likely not the result of enhanced ability of lineage 2 strains to survive and mutate in the presence of drug, and we find no evidence of strong fitness effects that would explain the observed differences in the rate at which drug resistance is acquired. Notably, we do find evidence that the genetic context of a given M. tuberculosis strain can affect the range of observed mutations conferring resistance to a single drug. In our analysis, the lineage 2 strain HN878 was permissive for a broader range of rpoB mutations compared to the lineage 4 strain CDC-1551. However, this difference in target size is not sufficient to explain the observed difference in the rates at which rifampicin resistance occurs, suggesting that a basal difference in mutation before selection drives the accelerated rate at which drug resistance is acquired in the HN878 strain. In support of this notion, we find that HN878 more rapidly acquires resistance to not only rifampicin but also to isoniazid and ethambutol.
We also find significant variation in the mutation rates of the strains within each lineage. Previous analyses suggested that there is substantial genetic and phenotypic diversity among isolates from the various M. tuberculosis lineages 48 . We expect that differences in mutation rate and in target size both contribute to the 2-to 35-fold differences in the rates at which rifampicin resistance is acquired that we have measured in these other strains. Further work will be required to establish the relative contribution of these factors to the rate of acquisition of drug resistance for each strain and to determine to what extent these findings can be generalized to strains from other M. tuberculosis lineages.
To establish the in vivo relevance of these findings, we sought to assess the concordance between mutation rates measured in vitro and in vivo. Notably, we found that the mutation rate of M. tuberculosis in vitro is very close to the mutation rate-assessed as mutation per unit time-in isolates from a human transmission chain. Thus, M. tuberculosis acquires mutations at a similar rate over time in people as it does in an actively growing culture in vitro. This observation is consistent with our previous finding that the in vitro mutation rate over time was similar to the rate of mutation over time in M. tuberculosis isolated from macaques with latent and active disease. Taken together, these findings define a molecular clock for M. tuberculosis that may be used in future evolutionary and epidemiological studies, although care must be taken to identify and compensate for potential sources of variation in mutation rate 49, 50 .
We propose two possible explanations for the finding that M. tuberculosis acquires mutations at the same rate over time in vitro, in macaques and across a human transmission chain. First, there may be a population of M. tuberculosis replicating in vivo at a rate similar to the replication rate in vitro. These bacteria may be overrepresented in culturable clinical isolates, suggesting that they may be more likely to cause disease and be transmitted. Alternatively, it is possible that the mutation rate of M. tuberculosis is driven by a timedependent rather than a replication-dependent factor. For example, the replicative error rate in M. tuberculosis could be very low with respect to time, and mutations may occur both in vitro and in vivo largely through DNA damage from endogenous metabolic processes or exogenous stressors.
We expect that these models may be resolved in part by elucidating the molecular basis of strain-based differences in mutation rate. The differences in mutation rate among the clinical M. tuberculosis strains measured here are more modest than the differences that distinguish Figure 7 A stochastic simulation mathematical model predicts the emergence of multidrugresistant tuberculosis before the onset of treatment. (a) Estimates of the probability of observing MDR in a population were derived using a stochastic mathematical model of resistance in 200,000 simulations, 100,000 for each for the strains from lineage 2 and lineage 4. Model parameters are listed in supplementary table 6. Bacterial burden at diagnosis is shown on the x axis, and the probability of observing resistance is shown on the y axis in log scale. (b,c) To determine the sensitivity of our model to variations in growth rate (b) and fitness (c), we varied each parameter (supplementary table 6 ) and determined the probability of observing resistance (z axis, log scale) at any given bacterial burden (y axis, log scale) for a specified parameter set (x axis).
npg clinical isolates of other bacteria such as Pseudomonas aeruginosa and Escherichia coli [51] [52] [53] . Clinical isolates of these pathogens may become orders of magnitude more mutable than wild-type strains through the loss of mismatch repair 51 . However, mycobacteria, like all other actinomycetes, lack mismatch repair entirely 54, 55 , and the molecular basis of replicative fidelity in mycobacteria remains unclear. Although mutations in DNA replication and repair genes are enriched in some M. tuberculosis strains from lineage 2 (ref. 30) , no single point mutation has been found to accelerate the basal mutation rate of M. tuberculosis in isogenic strains. Notably, lineage 2 strains also differ from lineage 4 strains in important metabolic pathways 56, 57 . Thus, it is possible that genetic differences outside of those affecting DNA replication and repair contribute to the differences in mutation rate that we have measured.
We have used the observation that M. tuberculosis mutates at a constant rate per unit time to develop a predictive model of the evolution of MDR in vivo. Our model demonstrates that it is possible to observe the evolution of MDR before the onset of treatment, consistent with the predictions of a previous replication-dependent model 47 . Moreover, differences in mutation rate have approximately multiplicative effects for each mutation acquired, leading to stark differences in the de novo emergence of MDR. Indeed, we parameterized our model with data from the HN878 strain, which has only modestly elevated acquisition rates of rifampicin and isoniazid resistance. Strain X005632 has a 35-fold higher rate for the development of rifampicin resistance compared to CDC-1551. With X005632 having a similarly elevated rate for isoniazid resistance, the risk of MDR in an individual infected with X005632 would be nearly three orders of magnitude higher than for an individual infected with CDC-1551. Predicted differences in the occurrence of at least one multidrug-resistant bacterium within infected individuals may not be directly proportional to the clinical risk of drug-resistant tuberculosis because individual bacteria may not have equal capacity to cause disease. However, the magnitude of these differences suggests that strain-based variation in the acquisition of drug resistance is a key risk factor in the development of drug-resistant disease. Indeed, just as strains with higher mutation rates have increased risk of acquiring mutations that confer drug resistance and mutations that facilitate the acquisition of drug resistance (for example, those affecting efflux pumps [58] [59] [60] ), these strains have increased capacity to acquire compensatory mutations 61 that may enhance their fitness in vivo.
Although our model focused on the evolution of MDR (rifampicin and isoniazid resistance), the findings are applicable to the evolution of resistance to any antibiotic. New antibiotics and novel regimens of new and current antibiotics are being developed, combining drugs for which resistance is not yet prevalent. The expectation is that, with proper implementation, a novel regimen will treat patients infected with multidrug-resistant M. tuberculosis and prevent the emergence of resistance to new drugs 62, 63 . However, both clinical and highresolution sequencing findings suggest that patients in whom therapy is unsuccessful are infected with strains that are resistant to only a subset of the antibiotics administered 14, 15, 64 . Thus, even in the context of a novel regimen, resistance to these new antibiotics may be difficult to avoid, especially in the context of infection by strains from lineage 2.
Consistent with epidemiological data suggesting that severe disease at diagnosis is associated with the acquisition of MDR in new cases 65, 66 , our model also predicts that bacterial burden is a key determinant of the probability of drug resistance. In the face of substantial capacity for mutation and resistance, early and active case detection with novel, sensitive point-of-care diagnostics remains our best hope of curbing the drug resistance epidemic. Smear microscopy is the most common primary diagnostic for M. tuberculosis around the world but is orders of magnitude less sensitive than both culture and molecular diagnostics 67, 68 . If, as our model suggests, higher bacterial burden at diagnosis results in increased risk for the evolution of multidrug-resistant M. tuberculosis, then improving diagnostic sensitivity will not only curtail ongoing transmission of disease, as previously suggested 69, 70 , but will also limit the de novo emergence of drug resistance. The risk of drug resistance seems to be even greater in the setting of infection with lineage 2 strains of M. tuberculosis. Taken together, these data emphasize that M. tuberculosis strains differ in their propensity for acquiring drug resistance and suggest that these biological factors should be considered in efforts to limit the emergence of new resistance to both existing antibiotics and new treatment regimens.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession code. Whole-genome sequencing of human isolates was performed previously 42 , and reads were deposited in the NCBI Sequence Read Archive (SRA) under accession SRA020129. 
Note: Supplementary information is available in the online version of the paper.
ACKnowLedGMenTS
ONLINE METhODS
Culture and MIC determination of clinical isolates. Clinical strains were identified as previously described 71 . Strains were grown in broth culture of Middlebrook 7H9 supplemented with 10% Middlebrook oleic acid, albumin, dextrose and catalase solution (OADC), 0.0005% Tween-80 and 0.005% glycerol.
To determine MIC, strains were grown to log phase (optical density (OD) of 0.5-0.8) and diluted to an OD of 0.006. Wells were inoculated with 50 µl of culture and then supplemented with 50 µl of medium containing the appropriate concentration of antibiotic. All concentrations were tested in triplicate, and two sets of triplicate control wells were established for each strain. After 6 d, 10 µl of alamar blue (Life Technologies) was added to each well of one triplicate set of controls, where control wells were not supplemented with antibiotic. If control wells changed color from blue to pink after 24 h, 10 µl of alamar blue was added to each triplicate set of experimental wells as well as to a new set of control wells. All wells were examined after 24 h. Any wells that remained blue indicated inhibition of growth. The following concentrations were tested: 0.5, 0.25, 0.125, 0.06125, 0.03063 and 0.01531 µg/ml rifampicin (Sigma, R3501) and 0.25, 0.125, 0.06125, 0.03063, 0.01531 and 0.00766 µg/ml isoniazid (Sigma, I3377). MIC was defined as the lowest concentration of antibiotic that prevented color change from blue to pink. Fluctuation analysis. Fluctuation analysis was performed as previously described 6 . Briefly, for a single strain of M. tuberculosis, starter cultures were inoculated from freezer stocks of culture at OD = 1.0. Once the culture reached an OD of between 0.7 and 1.1, approximately 300,000 cells were used to inoculate 120 ml of 7H9 supplemented with 10% OADC, 0.0005% Tween-80 and 0.005% glycerol, giving a total cell count of 10,000 cells per 4-ml culture. This volume was immediately divided to start 24 cultures of 4 ml each in 30-ml square PETG culture bottles (Nalgene). Cultures were grown at 37 °C with shaking for 11 to 14 d, until reaching an OD of 1.0. Once at an OD of 1.0, 20 cultures were transferred to 15-ml conical tubes and spun at 3,220g for 10 min at 4 °C. Cultures were then resuspended in 250-500 µl of 7H9 supplemented with OADC, Tween-80 and glycerol and spotted onto plates with the same medium supplemented with 0.5, 2 or 5 µg/ml rifampicin, 1 µg/ml isoniazid or 5 µg/ml ethambutol (MP Biomedicals, 157949). Once spread using sterile glass beads (4 mm in diameter), plates were allowed to dry and were subsequently incubated at 37 °C for 28 d. Cell counts were determined by serial dilution of four cultures for each strain. The rate at which drug resistance was acquired was determined by calculating m (the estimated number of mutations per culture) based on the number of mutants (r) observed on each plate using the Ma, Sarkar, Sandri (MSS) method as previously described 33, 35 . Dividing m by N t , the number of cells plated for each culture, gives an estimated rate at which drug resistance emerged. We estimated 95% confidence intervals using equations (24) and (25) as described 33, 36 . For comparing pairs of fluctuation analysis data (Fig. 2) , the nonparametric twosided Wilcoxon rank-sum test (also known as the Mann-Whitney U test) was performed using the ranksum command in Matlab with α set to 0.05, comparing the frequency of drug-resistant mutants in each culture.
Analysis of data from fluctuation analysis.
To estimate the extent to which the data met the assumptions of Luria-Delbrück fluctuation analysis, we performed a curve-fitting analysis as described 35 . Briefly, data were fit using either a one-parameter model consistent with the Luria-Delbrück model or a twoparameter model containing an additional parameter describing a Poisson distribution. The fit of each model was assessed using least-squares methodology 35 , with AIC C calculated as described previously 39 . Lower AIC C reflects better fit given a penalty for increasing the number of parameters, and negative ∆AIC C (AIC C (one-parameter model) -AIC C (two-parameter model)) indicates that the one-parameter model is a better approximation of the data.
Determination of target size. The numbers of rpoB mutations conferring resistance to 0.5, 2 and 5 µg/ml rifampicin were determined by transferring 100 colonies (5 from each fluctuation analysis culture) into 100 µl of 7H9 supplemented with 10% OADC, 0.0005% Tween-80 and 0.005% glycerol. Cultures were grown overnight at 37 °C and were then heat inactivated at 85 °C for 2 h. Heat-inactivated cultures were used as templates for PCR and sequencing with previously described primers 72 . Sequences were analyzed for mutation relative to the reference sequence H37Rv, and total numbers of mutations were determined. For each culture, duplicate mutations were only counted once. The absolute number of unique mutations observed across cultures for a given condition was used to determine target size for each strain under each condition.
Estimation of mutation rate from human isolates.
To determine the per-base per-day mutation rate in human isolates, phylogenies were created using the concatenated SNP sequences reported from a clonal outbreak of a lineage 4 strain in British Columbia, Canada 42 , employing BEAST v. 1.7.2 (refs. 43,44) to perform Bayesian MCMC analysis. Before phylogenetic analysis, SNPs located in repeat regions (PE_PGRSs, PPEs and transposable elements) were excluded, consistent with our previous experimentally validated analysis of SNPs from whole-genome sequencing to estimate mutation rate 6 . Concatenated SNP sequences were compiled and prepared using BEAUti v1.7.2 to select analysis parameters and construct the XML input file. Concatenated sequences were converted to NEXUS format and loaded into BEAUti, where time was noted for each isolate. Time was defined in days based on the time elapsed from isolation of the historical isolate MT0005 (in 1995) to symptom onset from the isolate. A generalized time-reversible (GTR) substitution model was used with empirically determined base frequencies. Default priors were used for 10 million chains. Output was analyzed in Tracer v1.5, and all parameters produced an effective sample size of 200 or greater. Phylogenetic tree construction was completed using TreeAnnotator v1.7.2 with a posterior probability limit of 0.5 and a burn-in of 1,000 trees, leaving 9,001 potential trees for construction. Tree visualization was completed using FigTree v1.3.1, and the tree was rooted on MT0005; the most likely tree is depicted in Supplementary Figure 1 .
Mathematical simulation of drug resistance. We developed a compartmental, partially stochastic mathematical model of the evolution of drug resistance within an individual according to the following set of equations:
the probability of observing drug resistance with a given set of parameters.
To determine the effect of varying birth rate, 10 simulations of 200,000 simulated infected individuals (100,000 per simulated strain) were each run with b = (0.20:1.10 in increments of 0.10), giving a net birth rate of 0.05:0.95. To determine the effect of varying the fitness of drug-resistant mutants, 10 simulations of 200,000 infected individuals each (100,000 per simulated strain) were run with cr H = cr R = (0.0: 0.90 in increments of 0.10). For all simulations, bacterial burden was allowed to increase to 1 × 10 12 bacteria in an infected individual, and the probabilities of observing rifampicin resistance, isoniazid resistance and MDR were determined by dividing the number of simulated individuals with at least one resistant bacterium by the total number of simulated individuals.
To determine the probability of observing resistance in a model where mutation is determined by replication dynamics, we used equation (2) from ref. 47 with the parameters listed in Supplementary Figure 2c . 71 
